
Leaders from across the healthcare ecosystem have recognized that the lack of a solid, agreed-upon evidence framework for genetic tests is a critical barrier to clear payer coverage policies, clinical guidelines, and ultimately, evidence-based patient care.
This December, clinical experts, researchers, and health plan leaders will gather for a virtual summit to define an evidence framework that really works for precision medicine in the 21st century.
There is no cost to participate or travel required – this event is entirely online.
If you wish to participate, please submit the form. You will receive more information about how to participate, and you will be registerd for the (optional) kickoff webinar on Mon Dec 9th at 12noon CT.
Reserve Your Space
GOALS
The goals of the summit are to:
1. Bring together key stakeholders from many perspectives to participate in online discussion forums from December 9th through December 20th.
2. Use the discussion forums to:
– Develop a consensus on the appropriate definitions of clinical utility, clinical validity, and cost-effectiveness for genomic testing
– Determine the necessary elements of an evidence framework for genomic testing
3. Report on our experience and summit outcomes through a whitepaper or peer-reviewed publication.
HOW IT WORKS
The process of this virtual summit will work as follows:
1. Complete the web form above to hold your spot. You will receive a confirmation email immediately. A separate email with log in credentials for the forum will arrive the week before the summit kickoff.
2. Block out some time on your calendar the weeks of December 9th and December 16th to participate in the online discussion. About 30 minutes per day is a good benchmark.
3. Read background documents in advance. When you complete the form above, your confirmation email will include a link to these documents.
4. On December 9th, join the kickoff webinar (details to follow). If you can’t make it, a recording will be available in the discussion forum.
5. Between December 9th- 20th, log in to the discussion forum and participate. The forum will be broken in to several sections and will contain polls and questions for you to answer. Moderators will be help clarify any points of interest or answer questions that come up
6. A summary paper will be prepared for distribution following the event.
Previous Organizers, Speakers & Authors
CARLOS BUSTAMANTE, PhD
Chair, Department of Biomedical Data Science
Stanford University
MARA ASPINALL
CEO
Health Catalysts Group
GILLIAN HOOKER, PhD, ScM, LCGC
VP, Clinical Development
Concert Genetics
SUZANNE BELINSON, PhD, MPH
VP, Commercial Markets
Tempus
ROBERT NUSSBAUM, MD
Chief Medical Officer
Invitae
DEE ANNA SMITH
CEO
Sarah Cannon
GEORGE CARDOZA
Senior Vice President, Chief Financial Officer
NeoGenomics
SEAN HOFHERR, PhD
Chief Scientific Officer
GeneDx, Inc.
JULIE M EGGINGTON, MS, PhD
Co-founder & CEO
Center for Genomic Interpretation
GERALD FELDMAN, MD, PhD
President
American College of Medical Genetics & Genomics
MARY FREIVOGEL, MS, CGC
President
National Society of Genetic Counselors
ERYNN GORDON, MS, LCGC
VP, Clinical Operations
Genome Medical
NIKOLETTA SIDIROPOULOS, MD
Medical Director, Genomic Medicine, Department of Pathology and Laboratory Medicine
University of Vermont Health Network
BAS VAN DER BAAN
Chief Clinical Officer
Agendia
HOWARD LEVY, MD, PhD
Associate Professor of Medicine
Johns Hopkins Medicine
LEE N. NEWCOMER, MD, MHA
SVP, Oncology and Genetics
UnitedHealthcare
BENJAMIN SOLOMON, MD, FACMG
Managing Director
GeneDx
ROBERT C. GREEN, MD, MPH
Director, Genomes2People
Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School
DAN RODEN, MD
Senior Vice President, Personalized Medicine
Vanderbilt University Medical Center
NICOLE BOICE
Founder & CEO
Global Genes
DAVID MCCALLIE, MD
SVP, Medical Informatics
Cerner
EDWARD ABRAHAMS, PhD
President
Personalized Medicine Coalition
TAHA KASS-HOUT, MD
Former 1st Chief Health Informatics Officer
U.S. Food and Drug Administration (FDA)
GIL ALTEROVITZ, PhD
Director, Biomedical Cybernetics Laboratory
Harvard Medical School
KRISTINE BORDENAVE, MD
Corporate Medical Director
Humana
JOSHUA DENNY, MD
Professor of Biomedical Informatics and Medicine
Vanderbilt University
HENRY GARLICH
Director, Healthcare Value Solutions & Enhanced Clinical Programs
Blue Shield of California
TRENT HAYWOOD, MD, JD
SVP & Chief Medical Officer
Blue Cross Blue Shield Association
KATHRYN LANG, MD
Global Medical Strategy Head of Data Science
Pfizer
MATT MIGHT, PhD
Director, Hugh Kaul Personalized Medicine Institute
University of Alabama at Birmingham
LAURIE MCGRAW
SVP, Health Solutions
American Medical Association
VICTORIA PRATT, PhD
President
Association for Molecular Pathology
DAWN BARRY
Co-Founder and President
Luna DNA
ELI CASDIN
Chief Investment Officer
Casdin Capital
ELLEN MATLOFF, MS, CGC
President & CEO
My Gene Counsel
JULIE RAMAGE
National Accounts Director, Diagnostics
Pfizer
ALEX DE WINTER
Managing Director
GE Ventures
NICK NACLERIO, PhD
Founding Partner
Illumina Ventures
EMILY EDELMAN, MS, CGC
Associate Director of Clinical & Continuing Education
The Jackson Laboratory
JAMES O’LEARY
Chief Innovation Officer
Genetic Alliance
BRYCE OLSON
Global Marketing Director, Health and Life Sciences
Intel